The Lancet Haematology· David J Kuter, Waleed Ghanima, Nichola Cooper, Howard A Liebman, Lei Zhang, Yu Hu, Yoshitaka Miyakawa, Marie Luise Hütter-Krönke, Cristina Pascual-Izquierdo, Elisa Lucchini, Sylvain Audia, Matias Cordoba, Heidi Krenz, Mengjie Yao, Ahmed Daak·· 2026-09-18精选AI 评分69
三期LUNA3试验开放期结果:Rilzabrutinib用于既往治疗过的免疫性血小板减少症的疗效与安全性
[Articles] Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial
AI 导读
Rilzabrutinib在三期LUNA3试验的开放标签期表现出持续且稳定的血小板反应,部分初始无反应患者出现改善,并改善了体力疲劳和出血等症状,安全性良好。
推荐理由
报道了rilzabrutinib在三期LUNA3试验开放期对既往治疗过的免疫性血小板减少症患者的持续疗效与安全性结果。
来源:The Lancet Haematology · thelancet.com